Linezolid for drug-resistant pulmonary tuberculosis

Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J. Sloan

doi:10.1002/14651858.cd012836.pub2

Linezolid for drug-resistant pulmonary tuberculosis

Bhagteshwar Singh, Derek Cocker, Hannah Ryan, Derek J. Sloan

Research output: Contribution to journal › Review article › peer-review

21 Citations (Scopus)

Abstract

Linezolid was recently re‐classified as a Group A drug by the World Health Organization (WHO) for treatment of multi‐drug resistant tuberculosis (MDR‐TB) and extensively drug‐resistant tuberculosis (XDR‐TB), suggesting that it should be included in the regimen for all patients unless contraindicated. Linezolid use carries a considerable risk of toxicity, with the optimal dose and duration remaining unclear. Current guidelines are mainly based on evidence from observational non‐comparative studies.

Original language	English
Article number	CD012836
Pages (from-to)	CD012836
Journal	Cochrane Database of Systematic Reviews
Volume	2019
Issue number	3
DOIs	https://doi.org/10.1002/14651858.cd012836.pub2
Publication status	Published - 20 Mar 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/14651858.cd012836.pub2Licence: CC BY-NC

Singh et al-2019-Cochrane Database of Systematic ReviewsFinal published version, 874 KBLicence: CC BY-NC

Cite this

@article{01a1841eee4549eab50749e3ee7ad2b8,

title = "Linezolid for drug-resistant pulmonary tuberculosis",

abstract = "Linezolid was recently re‐classified as a Group A drug by the World Health Organization (WHO) for treatment of multi‐drug resistant tuberculosis (MDR‐TB) and extensively drug‐resistant tuberculosis (XDR‐TB), suggesting that it should be included in the regimen for all patients unless contraindicated. Linezolid use carries a considerable risk of toxicity, with the optimal dose and duration remaining unclear. Current guidelines are mainly based on evidence from observational non‐comparative studies.",

author = "Bhagteshwar Singh and Derek Cocker and Hannah Ryan and Sloan, \{Derek J.\}",

year = "2019",

month = mar,

day = "20",

doi = "10.1002/14651858.cd012836.pub2",

language = "English",

volume = "2019",

pages = "CD012836",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Linezolid for drug-resistant pulmonary tuberculosis

AU - Singh, Bhagteshwar

AU - Cocker, Derek

AU - Ryan, Hannah

AU - Sloan, Derek J.

PY - 2019/3/20

Y1 - 2019/3/20

N2 - Linezolid was recently re‐classified as a Group A drug by the World Health Organization (WHO) for treatment of multi‐drug resistant tuberculosis (MDR‐TB) and extensively drug‐resistant tuberculosis (XDR‐TB), suggesting that it should be included in the regimen for all patients unless contraindicated. Linezolid use carries a considerable risk of toxicity, with the optimal dose and duration remaining unclear. Current guidelines are mainly based on evidence from observational non‐comparative studies.

AB - Linezolid was recently re‐classified as a Group A drug by the World Health Organization (WHO) for treatment of multi‐drug resistant tuberculosis (MDR‐TB) and extensively drug‐resistant tuberculosis (XDR‐TB), suggesting that it should be included in the regimen for all patients unless contraindicated. Linezolid use carries a considerable risk of toxicity, with the optimal dose and duration remaining unclear. Current guidelines are mainly based on evidence from observational non‐comparative studies.

U2 - 10.1002/14651858.cd012836.pub2

DO - 10.1002/14651858.cd012836.pub2

M3 - Review article

SN - 1465-1858

VL - 2019

SP - CD012836

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 3

M1 - CD012836

ER -

Linezolid for drug-resistant pulmonary tuberculosis

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this